Medicare Drug Price Reporting, Preferred Pharmacy Regs Get Makeover In CMS Rule
This article was originally published in The Pink Sheet Daily
In its proposed rule on Medicare Part D, CMS tackles issues it believes has led to distortions in drug price reporting by plans and a disconnect between drug prices and beneficiary cost-sharing levels.
You may also be interested in...
A proposed Medicare rule says under new criteria CMS has developed, antidepressants and immunosuppressants will no longer be protected classes in plan formularies, but antineoplastics, antiretrovirals and anticonvulsants will remain. Antipsychotics will also be protected through 2015 as CMS continues to evaluate the class.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.